cGMP-compliant manufacturing of EDV-based anti-cancer therapeutics for commercial licensing

Commercialisation Australia is supporting the development of cGMP-compliant manufacturing of the EnGeneIC delivery vehicle (EDV) based anti-cancer therapeutics for commercial licensing. Potential commercial partners seek assurance that EDV manufacturing can be scaled-up to cGMP standards, and are cost-effective, prior to agreeing licensing deals.

The project will contribute to the establishment of a globally unique manufacturing capability in a novel pharmaceutical delivery technology.

[Picture courtesy of EnGeneIC Limited]